Grufity logo
Grufity logo
OCUP

OCUP - Ocuphire Pharma, Inc. Stock Price, Fair Value and News

$6.04-0.03 (-0.49%)
Market Closed as of 11 Sep 2026, 04:00 pm ET

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

OCUP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OCUP Price Action

Last 7 days

29.3%

Last 30 days

60.6%

Last 90 days

49.5%

Trailing 12 Months

328.4%

OCUP RSI Chart

OCUP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OCUP Valuation

Market Cap

502.5M

Price/Earnings (Trailing)

-4.67

Price/Sales (Trailing)

50.98

EV/EBITDA

-3.86

Price/Free Cashflow

-12.36

OCUP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

OCUP Fundamentals

OCUP Revenue

Revenue (TTM)

9.9M

Rev. Growth (Yr)

-73.8%

Rev. Growth (Qtr)

-65%

OCUP Earnings

Earnings (TTM)

-107.6M

Earnings Growth (Yr)

-9.14%

Earnings Growth (Qtr)

87.64%

OCUP Profitability

EBT Margin

-1091.82%

Return on Equity

828.66%

Return on Assets

-115.75%

Free Cashflow Yield

-8.09%

OCUP Investor Care

Shares Dilution (1Y)

38.87%

Diluted EPS (TTM)

-1.34

Revenue & Growth

How Ocuphire Pharma, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202612.0M9.9M--
202513.7M15.4M14.6M14.2M
202419.0M16.4M8.4M11.0M
202334.6M29.4M24.2M19.0M
2022---39.9M
2021----
2020----
2019----
2018----
2017----
2016----
2015----
2014----
2013----
2012----
2011----
2010----
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Ocuphire Pharma, Inc.

OCUP
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate for dim light or night vision disturbances; and for pharmacologically induced mydriasis and presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. The company is headquartered in Farmington Hills, Michigan.
 CEO
 WEBSITEocuphire.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES9

Ocuphire Pharma, Inc. Frequently Asked Questions

OCUP is the stock ticker symbol of Ocuphire Pharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Sep 11 2026, market cap of Ocuphire Pharma, Inc. is 502.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Sep 11 2026, OCUP's PE ratio (Price to Earnings) is -4.67 and Price to Sales (PS) ratio is 50.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OCUP PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Ocuphire Pharma, Inc. has provided 0.089 (multiply by 100 for percentage) rate of return.